title: [Therapy of psychotic schizophrenia spectrum disorders in adolescents].
abstract: OBJECTIVE
  To assess the clinical efficacy, tolerability and safety of prolonged treatment with paliperidone in adolescents with the exacerbation of psychotic schizophrenia spectrum disorders.
  
  
  METHODS
  Thirty-six adolescents at the age from 14 to 18 years with ICD-10 diagnosis F20-21, F25 were examined by clinical/psychopathological method (PANSS and CGI scale). The duration of the disease was from 1 to 3 years. The duration of the study was 12 months.
  
  
  CONCLUSIONS
  The efficacy and safety of prolonged use of paliperidone in a dose of 3 to 12 mg/day in adolescents with schizophrenia spectrum disorders were identified.
authors.affiliation: Bekhterev St. Petersburg Psychoneurological Research Institute, St. Petersburg.
authors.forename: Yu V
authors.initials: YV
authors.lastname: Popov
authors.affiliation: Bekhterev St. Petersburg Psychoneurological Research Institute, St. Petersburg.
authors.forename: Yu A
authors.initials: YA
authors.lastname: Yakovleva
authors.affiliation: Bekhterev St. Petersburg Psychoneurological Research Institute, St. Petersburg.
authors.forename: M V
authors.initials: MV
authors.lastname: Pisevich
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D000068882:Paliperidone Palmitate / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D000068882:Paliperidone Palmitate